Table 3.

Adverse events by preferred term- single ascending-dose study (Part 1).

	Anti-SARS-CoV-2 IgY
	2 mg	4 mg	8 mg	Placebo	All Participants
	(N=6)	(N=6)	(N=6)	(N=6)	(N=24)
	n (%) E	n (%) E	n (%) E	n (%) E	n (%) E
Participants with ≥1 TEAE	1 (16.7%) 1	2 (33.3%) 2	2 (33.3%) 2	2 (33.3%) 2	7 (29.2%) 7
MedDRA Preferred Term
Fatigue	0	0	1 (16.7%) 1	1 (16.7%) 1	2 (8.3%) 2
Erythema	0	0	1 (16.7%) 1	0	1 (4.2%) 1
Headache	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Sneezing	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Tension headache	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Thermal burn	0	0	0	1 (16.7%) 1	1 (4.2%) 1

E, number of events; n, number of participants; TEAE, treatment-emergent adverse event.